Characterization and modulation of drug resistance of human paediatric rhabdomyosarcoma cell lines

British Journal of Cancer

Volumn 83, Issue 3, 2000, Pages 338-345

  Cocker, H A ^a   Pinkerton, C R ^b   Kelland, L R ^a  

^a INSTITUTE OF CANCER RESEARCH   (United Kingdom)

^b INSTITUTE OF CANCER RESEARCH   (United Kingdom)

Author keywords

MDR 1; Modulation; Resistance; Rhabdomyosarcoma

Indexed keywords

ANTHRACYCLINE DERIVATIVE; BIRICODAR; CISPLATIN; CYCLOPHOSPHAMIDE; DOXORUBICIN; ETOPOSIDE; GLYCOPROTEIN P; MESSENGER RNA; MULTIDRUG RESISTANCE PROTEIN; PROTEIN P53; VALSPODAR; VINCA ALKALOID; VINCRISTINE;

ARTICLE; DRUG UPTAKE; GENE MUTATION; GENE OVEREXPRESSION; HUMAN; HUMAN CELL; IMMUNOBLOTTING; PRIORITY JOURNAL; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; RHABDOMYOSARCOMA;

EID: 0033936288     PISSN: 00070920     EISSN: None     Source Type: Journal    
DOI: 10.1054/bjoc.2000.1273     Document Type: Article

References (38)

1. Barrand MA, Heppell-Parton AC, Wright KA, Rabbitts PH and Twentyman PR (1994) A 190-kDa protein overexpressed in non-P-glycoprotein-containing multidrug-resistant resistant cells and its relationship to the MRP gene. J Natl Cancer Inst 86: 110-117
2. Bordow SB, Haber M, Madafiglio J, Cheung B, Marshall GM and Norris MD (1994) Expression of the multidrug resistance-associated protein (MRP) gene correlates with amplification and overexpression of the N-myc oncogene in childhood neuroblastoma. Cancer Res 54: 5036-5040
3. Chan HSL, Thorner PS, Haddad G and Ling V ( 1990) Immunohistochemical detection of P-glycoprotein - Prognostic correlation in soft-tissue sarcoma of childhood. J Clin Oncol 8: 689-704
4. Chaudhary and Roninson (1993) Induction of multidrug resistance in human cells by transient exposure to different chemotherapeutic drugs. J Natl Cancer Inst 85: 632-639
5. Cole SPC, Bhardwaj G, Gerlach JH, Mackie JE, Grant CE, Almquist KC, Stewart AJ, Kurz EU, Duncan AMV and Deeley RG (1992) Overexpression of a transporter gene in a multidrug-resistant human lung cancer cell line. Science 258: 1650-1654
6. Cowie FJ, Pinkerton CR, Phillips M, Dick G, Judson I, McCarthy PT and Flanagan RJ (1995) Continuous-infusion verapamil with etoposide in relapsed or resistant paediatric cancers. Br J Cancer 71: 877-881
7. Cowie FJ, Pritchard-Jones K, Renshaw J and Pinkerton CR (1998) Multidrug resistance modulation in rhabdomyosarcoma and neuroblastoma cell lines. Int J Oncol 12: 1143-1149
8. Douglass EC, Valentine M, Etcubanas E, Parham D, Webber BL, Houghton PJ, Green AA and Houghton JA (1987) A specific chromosomal abnormality in rhabdomyosarcoma. Cytogenet Cell Genet 45: 148-155
9. Enzinger FM and Weiss SW (1983) Soft Tissue Tumours. CV Mosby Co: St. Louis
10. Enzinger FM and Weiss SW (1995) Soft Tissue Tumours. 3rd Edn. CV Mosby Co: St. Louis
11. Felix CA, Chavez Kappel C, Mitsudomi T, Nau MM, Tsokos M, Crouch GD, Nisen PD, Winick NJ and Helman LJ (1992) Frequency and diversity of p53 mutations in childhood rhabdomyosarcoma. Cancer Res 52: 2243-2247
12. Ford JM (1996) Experimental reversal of P-glycoprotein-mediated multidrug resistance by pharmacological chemosensitisers. Eur J Cancer 32A: 991-1001
13. Garvin AJ, Stanley WS, Bennett DD, Sullivan JL and Sens DA (1986) The in vitro growth, heterotransplantation, and differentiation of a human rhabdomyosarcoma cell line. Am J Pathol 125: 208-217
14. Germann UA, Shlyakhter D, Mason VS, Zelle RE, Duffy JP, Galullo V, Armistead DM. Saunders JO, Boger J and Harding MW (1997a) Cellular and biochemical characterization of VX-710 as a chemosensitizer: reversal of P-glycoprotein-mediated multidrug resistance in vitro. Anticancer Drugs 8: 125-140
15. Germann UA, Ford PJ, Shlyakhter D, Mason VS and Harding MW (1997b) Chemosensitization and drug accumulation effects of VX-710, verapamil, cyclosporin A, MS-209 and GF120918 in multidrug resistant HL60/ADR cells expressing the multidrug resistance-associated protein MRP. Anticancer Drugs 8: 141-155
16. Hayashi Y, Sugimoto T, Horii Y, Hosoi H, Inazawa J, Kemshead JT, Inaba T, Hanada R, Yamamoto K, Gown AM and Sawada T (1990) Characterization of an embryonal rhabdomyosarcoma cell line showing amplification and over-expression of the N-myc oncogene. Int. J. Cancer 45: 705-711
17. Houghton JA, Houghton PJ and Webber BL (1982) Growth and characterization of childhood rhabdomyosarcoma as xenografts. J Natl Cancer Inst 68: 437-443
18. Keleti J, Quezado MM, Abaza MM, Raffeld M and Tsokos M (1996) The MDM2 oncoprotein is overexpressed in rhabdomyosarcoma cell lines and stabilizes wild-type p53 protein. Am J Pathol 149: 143-151
19. Kelland LR, Bingle L, Edwards S and Steel GG (1989) High intrinsic radiosensitivity of a newly established and characterised human embryonal rhabdomyosarcoma cell line. Br J Cancer 59: 160-164
20. Kondo S, Kondo Y, Hara H, Kaakaji R, Peterson JW, Morimura T, Takeuchi J and Barnett GH (1996) mdm2 gene mediates the expression of mdr1 gene and P-glycoprotein in a human glioblastoma cell line. Br J Cancer 74: 1263-1268
21. Kuttesch JF, Parham DM, Luo X, Meyer WH, Bowman L, Shapiro DN, Pappo AS, Crist WM, Beck WT and Houghton PJ ( 1996) P-Glycoprotein expression at diagnosis may not be a primary mechanism of therapeutic failure in childhood rhabdomyosarcoma. J Clin Oncol 14: 886-900
22. Lane DP (1992) p53, Guardian of the genome. Nature 358: 15-16
23. Lowry OH, Rosebrough NJ, Lewis Fair A and Randall RJ (1951) Protein measurements with the folin phenol reagent. J Biol Chem 193: 265-275
24. McAllister RM, Melnyk J, Finkelstein JZ, Adams EC and Gardner MB (1969) Cultivation in vitro of cells derived from a human rhabdomyosarcoma. Cancer 24: 520-526
25. Mosmann T (1983) Rapid colorimetric assay for cellular growth and survival: application to proliferation and cytotoxicity assays, J Immunol Methods 65: 55-63
26. Naito M and Tsuruo T (1997) New multidrug-resistance-reversing drugs, MS-209 and SDZ PSC833. Cancer Chemother Pharmacol 40: S20-S24
27. O'Connor PM, Jackman J, Bae I, Myers TG, Fan S, Mutoh M, Scudiero DA, Monks A, Sausville EA, Weinstein JN, Friend S, Fornace AJ and Kohn KW (1997) Characterization of the p53 tumour suppressor pathway in cell lines of the National Cancer Institute anticancer drug screen and correlations with the growth-inhibitory potency of 123 anticancer agents. Cancer Res 57: 4285-4300
28. Pappo AS, Shapiro DN, Crist WM and Maurer HM (1995) Biology and therapy of paediatric rhabdomyosarcoma. J Clin Oncol 13: 2123-2139
29. Pestell KE, Medlow CJ, Titley JC, Kelland LR and Walton MI (1998) Characterisation of the P53 status, BCL-2 expression and radiation and platinum drug sensitivity of a panel of human ovarian cancer cell lines. Int J Cancer 77: 913-918
30. Pinkerton CR (1996) Multidrug resistance reversal in childhood malignancies - potential for a real step forward? Eur J Cancer 32A: 641-644
31. Scheper RJ, Broxterman HJ, Scheffer GL, Kaaijk P, Dalton WS, van Heijningen THM, van Kalken CK, Slovak ML, de Vries EGE. van der Valk P, Meijer CJLM and Pinedo HM (1993) Overexpression of a Mr 110,000 vesicular protein in non-P-glycoprotein-mediated multidrug resistance. Cancer Res 53: 1475-1479
32. Sharp SY, Rowlands MG, Jarman M, and Kelland LR (1994) Effects of a new antioestrogen, idoxifene, on cisplatin- and doxorubicin-sensitive and -resistant human ovarian carcinoma cell lines. Br J Cancer 70: 409-414
33. Sharp SY, Rogers P and Kelland LR (1995) Transport of cisplatin and bis-acetatoammine dichlorocyclohexamine platinum (IV) (JM216) in human ovarian carcinoma cell lines: Identification of a plasma membrane protein associated with cisplatin resistance. Clin Cancer Res 1: 981
34. Stein U, Walther W, Laurencot CM, Scheffer GL, Scheper RL and Shoemaker RH (1997) Tumour necrosis factor-a and expression of the multidrug resistance associated genes LRP and MRP. J Natl Cancer Inst 89: 807-813
35. Stratton MR, Moss S, Warren W, Patterson H, Clark J, Fisher C, Fletcher CDM, Ball A, Thomas M, Gusterson BA and Cooper CS (1990) Mutation of the p53 gene in human soft tissue sarcomas: association with abnormalities of the RB1 gene. Oncogene 5: 1297-1301
36. Towbin H, Staehelin T and Gordon J (1979) Electrophoretic transfer of proteins from polyacrylamide gels to nitrocellulose sheets: procedures and some applications. Proc. Natl Acad Sci USA 76: 350
37. Wurl P, Taubert H, Bache M, Kroll J, Meye A, Berger D, Siermann A, Holzhausen H-J, Hinze R, Schmidt H and Rath F-W (1996) Frequent occurrence of p53 mutations in rhabdomyosarcoma and leiomyosarcoma, but not in fibrosarcoma and malignant neural tumours. Int J Cancer 69: 317-323
38. Yanagisawa T, Newman A, Coley H, Renshaw J, Pinkerton CR and Pritchard-Jones K (1999) Biricodar (VX-710; Incel (TM)): An effective chemosensitiser in neuroblastoma. Br J Cancer 80: 1190-1196